Understanding risk is the first step in addressing hereditary cancer

We offer state-of-the-art technology, expertise, and more specialized oncology testing than any other lab, resulting in a knowledge and service base that makes cancer diagnostics more accessible, actionable, effective, and economical.

Comprehensive and Guideline-Based Hereditary Cancer Panels

The Comprehensive and Guideline-Based Hereditary Cancer Panels include genes associated with a broad spectrum of hereditary cancers. This can include, but is not limited to, cancers of the breast, colon, endometrium, ovary, pancreas, prostate, rectum, skin, neuroendocrine system, and other tissues.

Comprehensive Hereditary Cancer Panel

66 genes including emerging genes to help provide deeper genetic insights in order to make more informed decisions about your patient’s care

Guideline-Based Hereditary Cancer Panel

32 genes including moderate to high-risk to provide clinically actionable results that give you a clearer picture of your patient’s potential risk for hereditary cancers, including breast, colon, prostate, uterine, melanoma, and other hereditary cancers

Cancer-specific panels for hereditary breast, colorectal, and
endocrine cancers provide a clear picture of risk

Our hereditary cancer panels give you a clearer picture of a patient’s risk for certain hereditary cancers along with clinical insights that can help you and your patients make more informed decisions about the care pathway. The panels include genes selected following medically accepted guidelines and can be collected using saliva or blood.

Hereditary Breast Cancer Panel

16 genes associated with increased risk of breast cancer

Hereditary Colorectal Cancer Panel

19 genes associated with increased risk for colorectal cancer

Hereditary Endocrine Cancer Panel

12 genes associated with increased risk for paragangliomas, pheochromocytomas, and endocrine cancer

Hereditary Cancer Syndrome panels

We offer syndrome-specific tests that analyze genes that can be associated with different cancer syndromes such as BRCA-associated breast, ovarian, and pancreatic cancers; Lynch syndrome; familial adenomatous polyposis, and others.

Targeted single-gene and single-site tests

In some instances, a single-gene or single-site test may be preferred over a larger genetic testing panel. This is especially true when a patient’s diagnosis or family history is very suggestive for a certain syndrome or there is a known variant in the family.